PAVmed Inc PAVM

NAS: PAVM | ISIN: US70387R1068   7/11/2025
0,324 USD (+3,02%)
(+3,02%)   7/11/2025

30 oktober 2025 · PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025 · Persbericht

29 oktober 2025 · Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025 · Persbericht

15 oktober 2025 · Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit · Persbericht

25 september 2025 · Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors · Persbericht

16 september 2025 · Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs · Persbericht

11 september 2025 · Lucid Diagnostics Announces Closing of Public Offering of Common Stock · Persbericht

10 september 2025 · Lucid Diagnostics Announces Pricing of Public Offering of Common Stock · Persbericht

9 september 2025 · Lucid Diagnostics Announces Proposed Public Offering of Common Stock · Persbericht

5 september 2025 · Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025 · Persbericht

27 augustus 2025 · Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025 · Persbericht

26 augustus 2025 · PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology · Persbericht

14 augustus 2025 · PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results · Persbericht

13 augustus 2025 · Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results · Persbericht

5 augustus 2025 · Lucid Diagnostics to Participate in Upcoming Investor Conferences · Persbericht

31 juli 2025 · PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025 · Persbericht

30 juli 2025 · Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 · Persbericht

30 juli 2025 · PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule · Persbericht

16 juli 2025 · MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test · Persbericht

24 juni 2025 · PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing · Persbericht

18 juni 2025 · Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test · Persbericht

Mijn selecties